Loading patent…
AssigneeImmatics Biotechnologies GmbH
InventorsSabrina Kuttruff-Coqui, Toni Weinschenk, Jens Fritsche, Steffen Walter, Norbert Hilf, Oliver Schoor, Colette Song, Harpreet Singh
Estimating the term…
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
A method of treating a patient who has brain cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of IYGGHHAGF (SEQ ID NO:
A method of eliciting an immune response in a patient who has brain cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of IYGGHHAGF (SEQ ID NO:
Dependencies are inferred from the claim text.